Treatment
Sacituzumab govitecan clinical trials
We’re tracking 64 recruiting studies that include Sacituzumab govitecan, each written for real people, not researchers, below.
Recruiting studies
- NCT06238921RecruitingPhase 1/Phase 2
Study of two drugs and radiation for triple-negative breast cancer that spread to the brain
This trial tests adding the drugs sacituzumab govitecan and zimberelimab to targeted radiation therapy for people with triple-negative breast cancer that has spread to the brain. The goal is to see if this combination helps control the cancer longer.
Tampa, FloridaAges 18 years+ - NCT07339059RecruitingPhase 2
Maintenance therapy for advanced small cell lung cancer
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
Detroit, MichiganAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT07063212RecruitingPhase 2
Sacituzumab govitecan plus cetuximab for head and neck cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06248515RecruitingPhase 2
Sacituzumab govitecan for advanced thymic cancer
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT06401824RecruitingPhase 2
Combination drug therapy for lung cancer with brain spread
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
AmsterdamAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT03547973RecruitingPhase 2
Study of sacituzumab govitecan for advanced or non-removable bladder cancer
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
Tucson, ArizonaAges 18 years+ - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Long Beach, CaliforniaAges 18 years+ - NCT06926920RecruitingPhase 1/Phase 2
Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Birmingham, AlabamaAges 18 years+ - NCT07471776RecruitingPhase 2
Predicting ADC treatment response with PET scans in advanced breast cancer
This study uses special PET scans to see if a type of targeted therapy called an anti-TROP2 ADC will work well for your advanced breast cancer. The therapy is already part of your standard care; the scans help doctors understand how your tumor responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06065371RecruitingPhase 1
Sacituzumab govitecan plus capecitabine for advanced GI cancers
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
Detroit, MichiganAges 18 years+ - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06167317RecruitingPhase 1
Study of GS-0201 alone and combined for advanced solid tumors
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
Boston, MassachusettsAges 18 years+ - NCT06263543RecruitingPhase 2
Sequencing antibody-drug conjugates in ER+, HER2-low breast cancer
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
Miami, FloridaAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Duarte, CaliforniaAges 18 years+ - NCT06966141Recruiting
Real-World Study of Sacituzumab Govitecan for Breast Cancer
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT04986579RecruitingPhase 2
Scalp cooling to reduce hair loss during breast cancer chemotherapy
This Phase 2 trial tests whether using a scalp-cooling device during chemotherapy can help prevent or lessen hair loss in people with metastatic invasive breast cancer. You would need to be starting a specific chemotherapy plan and be willing to begin scalp cooling with your first treatment.
Boston, MassachusettsAges 18 years+ - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+
Common questions
- Are there clinical trials studying Sacituzumab govitecan?
- Yes. Clin2 currently lists 64 recruiting studies that include Sacituzumab govitecan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sacituzumab govitecan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sacituzumab govitecan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sacituzumab govitecan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.